RT Journal Article
SR Electronic
T1 <em>TP53, PIK3CA, FBXW7</em> and <em>KRAS</em> Mutations in Esophageal Cancer Identified by Targeted Sequencing
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 231
OP 238
VO 13
IS 3
A1 ZHENG, HUILI
A1 WANG, YAN
A1 TANG, CHUANNING
A1 JONES, LINDSEY
A1 YE, HUA
A1 ZHANG, GUANGCHUN
A1 CAO, WEIHAI
A1 LI, JINGWEN
A1 LIU, LIFENG
A1 LIU, ZHENCONG
A1 ZHANG, CHAO
A1 LOU, FENG
A1 LIU, ZHIYUAN
A1 LI, YANGYANG
A1 SHI, ZHENFEN
A1 ZHANG, JINGBO
A1 ZHANG, DANDAN
A1 SUN, HONG
A1 DONG, HAICHAO
A1 DONG, ZHISHOU
A1 GUO, BAISHUAI
A1 YAN, HE
A1 LU, QINGYU
A1 HUANG, XUE
A1 CHEN, SI-YI
YR 2016
UL http://cgp.iiarjournals.org/content/13/3/231.abstract
AB Background/Aim: Esophageal cancer (EC) is a common malignancy with significant morbidity and mortality. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in EC that may serve as biomarkers might help predict patient outcome and guide treatment. Traditionally, personalized cancer DNA sequencing was impractical and expensive. Recent technological advancements have made targeted DNA sequencing more cost- and time-effective with reliable results. This technology may be useful for clinicians to direct patient treatment. Materials and Methods: The Ion PGM and AmpliSeq Cancer Panel was used to identify mutations at 737 hotspot loci of 45 cancer-related genes in 64 EC samples from Chinese patients. Results: Frequent mutations were found in TP53 and less frequent mutations in PIK3CA, FBXW7 and KRAS. Conclusion: These results demonstrate that targeted sequencing can reliably identify mutations in individual tumors that make this technology a possibility for clinical use.